Akili (NASDAQ:AKLI – Get Free Report) and Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.
Analyst Ratings
This is a summary of recent ratings and target prices for Akili and Tandem Diabetes Care, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Akili | 0 | 0 | 1 | 0 | 3.00 |
| Tandem Diabetes Care | 0 | 1 | 12 | 0 | 2.92 |
Akili presently has a consensus target price of $4.00, indicating a potential upside of 834.58%. Tandem Diabetes Care has a consensus target price of $51.25, indicating a potential upside of 19.63%. Given Akili’s stronger consensus rating and higher possible upside, equities analysts plainly believe Akili is more favorable than Tandem Diabetes Care.
Risk & Volatility
Valuation and Earnings
This table compares Akili and Tandem Diabetes Care’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Akili | $1.68 million | 20.06 | -$59.49 million | ($0.61) | -0.70 |
| Tandem Diabetes Care | $747.72 million | 3.70 | -$222.61 million | ($2.17) | -19.74 |
Akili has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Akili, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
53.1% of Akili shares are held by institutional investors. 10.1% of Akili shares are held by insiders. Comparatively, 2.2% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Akili and Tandem Diabetes Care’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Akili | -2,492.04% | -79.93% | -59.16% |
| Tandem Diabetes Care | -18.37% | -34.38% | -10.91% |
Summary
Akili beats Tandem Diabetes Care on 9 of the 14 factors compared between the two stocks.
About Akili
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Receive News & Ratings for Akili Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akili and related companies with MarketBeat.com's FREE daily email newsletter.
